Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
C. Fenwick, P. Turelli, Y. Duhoo, K. Lau, C. Herate, R. Marlin, M. Lamrayah, J. Campos, L. Leuenberger, A. Farina, c. raclot, V. Genet, F. Fiscalini, J. Cesborn, L. Perez, , G. Pantaleo
bioRxiv · Jul 18, 2023 · PreprintMicrobiology
D. Lecuyer, R. Nardacci, D. Tannous, E. Gutierrez-Mateyron, A. Deva-Nathan, F. Subra, C. Di Primio, P. Quaranta, V. Petit, C. Richetta, A. Mostefa-Kara, F. Del Nonno, L. Falasca, R. Marlin, P. Maisonnasse, , J.-L. Perfettini
This study identifies P2X7 and NLRP3 inflammasome as host factors required for SARS-CoV-2 infection and shows their role in promoting viral replication.
bioRxiv · Apr 5, 2023Microbiology
C. Herate, R. Marlin, F. Touret, N. D. Bosquet, F. Donati, F. Relouzat, L. Junges, M. Galhaut, O. Dehan, Q. Sconosciutti, A. Nougairede, X. de Lamballerie, S. van der Werf, R. Le Grand
This study shows Sotrovimab remains effective against SARS-CoV-2 BQ.1.1 in a non-human primate model, as measured by reduced viral replication.
bioRxiv · Feb 15, 2023Pathology
A. Marc, R. Marlin, F. Donati, M. Prague, M. Kerioui, C. Herate, M. Alexandre, N. Dereuddre-bosquet, J. Bertrand, V. Contreras, S. Behillil, P. Maisonnasse, S. Van Der Werf, R. Le Grand, J. Guedj
This study examines how SARS-CoV-2 variants of concern affect viral dynamics in non-human primates, finding that most variants escape immune responses, with delta and omicron showing significant differences in viral production rates.
bioRxiv · Nov 9, 2022Microbiology
C. Fenwick, P. Turelli, D. Ni, L. Perez, K. Lau, E. Lana, C. Pellaton, C. Raclot, L. Esteves-Leuenberger, J. Campos, A. Farina, F. Fiscalini, C. Herate, R. Marlin, R. Abdelnabi, , G. Pantaleo
This paper identifies a potent human monoclonal antibody, P2G3, that neutralizes multiple SARS-CoV-2 variants including Omicron, and demonstrates its protective efficacy in a monkey model.
bioRxiv · Mar 18, 2022 · PreprintImmunology
M. Alexandre, R. Marlin, M. Prague, C. Severin, N. Kahlaoui, S. Cardinaud, T. Naninck, B. Delache, M. Surenaud, M. Galhaut, N. Dereuddre-Bosquet, M. Cavarelli, P. Maisonnasse, M. Centlivre, C. Lacabaratz, , R. Thiebaut
A mathematical model of viral dynamics is used to identify mechanistic correlates of protection in SARS-CoV-2 vaccines across three non-human primate studies.
bioRxiv · Oct 29, 2021Immunology
G. Sulbaran, P. Maisonnasse, A. Amen, D. Guilligay, N. Bosquet, J. A. Burger, M. Poniman, M. Buisson, S. D. Dylon, T. Naninck, J. Lemaitre, W. Gros, A.-S. Gallouet, R. Marlin, C. Bouillier, , W. Weissenhorn
This study develops a synthetic SARS-CoV-2 S glycoprotein virus-like particle vaccine that protects macaques from infection through strong antibody and T cell responses.
bioRxiv · Jul 26, 2021Immunology
P. J. M. Brouwer, M. Brinkkemper, P. Maisonnasse, N. Dereuddre-Bosquet, M. Grobben, M. Claireaux, M. de Gast, R. Marlin, V. Chesnais, S. Diry, J. D. Allen, Y. Watanabe, J. M. Griezen, G. Kerster, H. L. Turner, , de Bree
This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.
bioRxiv · Nov 7, 2020Immunology